High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center

Abstract Background: Reports dealing with clinical outcomes of classical Hodgkin's lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkin's lymphoma from a single institution in Latin America. Method: A retrospective study was conducted over ten years of patients with classical Hodgkin's lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes. Main results: One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remission. Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received a transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355 (p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin's lymphoma patients diagnosed at advanced stages had a low progression-free survival but an overall survival similar to high-income countries. Conclusion: Patients diagnosed with classical Hodgkin's lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and presented with advanced disease, underscoring the need for earlier diagnosis and improved contemporary therapeutic strategies in these mainly young productive-age Hodgkin's lymphoma patients.

Saved in:
Bibliographic Details
Main Authors: Jaime-Pérez,José Carlos, Gamboa-Alonso,Carmen Magdalena, Padilla-Medina,José Ramón, Jiménez-Castillo,Raúl Alberto, Olguín-Ramírez,Leticia Alejandra, Gutiérrez-Aguirre,César Homero, Cantú-Rodríguez,Olga Graciela, Gómez-Almaguer,David
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2017
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400325
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-84842017000400325
record_format ojs
spelling oai:scielo:S1516-848420170004003252017-12-08High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American centerJaime-Pérez,José CarlosGamboa-Alonso,Carmen MagdalenaPadilla-Medina,José RamónJiménez-Castillo,Raúl AlbertoOlguín-Ramírez,Leticia AlejandraGutiérrez-Aguirre,César HomeroCantú-Rodríguez,Olga GracielaGómez-Almaguer,David Classic Hodgkin's lymphoma Refractory Hodgkin's lymphoma ABVD Survival rates Latin America Abstract Background: Reports dealing with clinical outcomes of classical Hodgkin's lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkin's lymphoma from a single institution in Latin America. Method: A retrospective study was conducted over ten years of patients with classical Hodgkin's lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes. Main results: One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remission. Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received a transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355 (p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin's lymphoma patients diagnosed at advanced stages had a low progression-free survival but an overall survival similar to high-income countries. Conclusion: Patients diagnosed with classical Hodgkin's lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and presented with advanced disease, underscoring the need for earlier diagnosis and improved contemporary therapeutic strategies in these mainly young productive-age Hodgkin's lymphoma patients.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.39 n.4 20172017-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400325en10.1016/j.bjhh.2017.08.001
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Jaime-Pérez,José Carlos
Gamboa-Alonso,Carmen Magdalena
Padilla-Medina,José Ramón
Jiménez-Castillo,Raúl Alberto
Olguín-Ramírez,Leticia Alejandra
Gutiérrez-Aguirre,César Homero
Cantú-Rodríguez,Olga Graciela
Gómez-Almaguer,David
spellingShingle Jaime-Pérez,José Carlos
Gamboa-Alonso,Carmen Magdalena
Padilla-Medina,José Ramón
Jiménez-Castillo,Raúl Alberto
Olguín-Ramírez,Leticia Alejandra
Gutiérrez-Aguirre,César Homero
Cantú-Rodríguez,Olga Graciela
Gómez-Almaguer,David
High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
author_facet Jaime-Pérez,José Carlos
Gamboa-Alonso,Carmen Magdalena
Padilla-Medina,José Ramón
Jiménez-Castillo,Raúl Alberto
Olguín-Ramírez,Leticia Alejandra
Gutiérrez-Aguirre,César Homero
Cantú-Rodríguez,Olga Graciela
Gómez-Almaguer,David
author_sort Jaime-Pérez,José Carlos
title High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
title_short High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
title_full High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
title_fullStr High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
title_full_unstemmed High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center
title_sort high frequency of primary refractory disease and low progression-free survival rate of hodgkin's lymphoma: a decade of experience in a latin american center
description Abstract Background: Reports dealing with clinical outcomes of classical Hodgkin's lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkin's lymphoma from a single institution in Latin America. Method: A retrospective study was conducted over ten years of patients with classical Hodgkin's lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes. Main results: One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remission. Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received a transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355 (p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin's lymphoma patients diagnosed at advanced stages had a low progression-free survival but an overall survival similar to high-income countries. Conclusion: Patients diagnosed with classical Hodgkin's lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and presented with advanced disease, underscoring the need for earlier diagnosis and improved contemporary therapeutic strategies in these mainly young productive-age Hodgkin's lymphoma patients.
publisher Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publishDate 2017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400325
work_keys_str_mv AT jaimeperezjosecarlos highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT gamboaalonsocarmenmagdalena highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT padillamedinajoseramon highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT jimenezcastilloraulalberto highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT olguinramirezleticiaalejandra highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT gutierrezaguirrecesarhomero highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT canturodriguezolgagraciela highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
AT gomezalmaguerdavid highfrequencyofprimaryrefractorydiseaseandlowprogressionfreesurvivalrateofhodgkinslymphomaadecadeofexperienceinalatinamericancenter
_version_ 1756423620364599296